Inflammatory and thrombotic mechanisms in coronary atherosclerosis

Heart

Volumn 89, Issue 9, 2003, Pages 993-997

  Tousoulis, Dimitris ^a   Davies, G ^b   Stefanadis, C ^a   Toutouzas, P ^a   Ambrose, J A ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; HEMOSTASIS; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; MACROPHAGE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THROMBOSIS;

EID: 0041326889     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.9.993     Document Type: Review

References (86)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995;91:2488-96.
3. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996;7:330-5.
4. Sato T, Takebayashi S, Kohchi K. Increased subendothelial infiltration of the coronary arteries with monocytes/macrophages in patients with unstable angina: histological data on 14 autopsied patients. Atherosclerosis 1987;68:191-7.
5. van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
6. Kohchi K, Takeboyashi S, Hirok T, et al. Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy. Circulation 1985;71:709-16.
7. Stamenkovic I, Stegagno M, Wright KA, et al. Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci USA 1988;85:1179-83.
8. Helmer ME, Ware CF, Strominger JL. Characterization of a novel differentiation antigen complex recognized by a monoclonal antibody (A-1A5): unique activation-specific molecular forms on stimulated T-cells. J Immunol 1983;131:334-40.
9. Burmester GR, John B, Gramatski M, et al. Activated T-cells in vivo and in vitro: divergence in expression of Tac and la antigens in the non-blastoid small T-cells of inflammation and normal T-cells activated in vitro. J Immunol 1984;133:1230-4.
10. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997;95:2387-94.
11. Aukrust P, Muller FM, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T-lymphocyte and platelet involvement into pathogenesis of acute coronary syndromes. Circulation 1999;100:614-20.
12. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risks of developing periphera vascular disease. Circulation 1998;97:425-8.
13. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
14. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
15. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T, in acute coronary syndromes. J Am Coll Cardiol 1998;31:1460-5.
16. Ridker P, Vaughan D, Stampfer M, et al. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
17. Ridker P, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
18. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998;279:1477-82.
19. Koenig W. Fibrinogen and coronary risk. In: Fuster V, ed. Novel risk factors and the prevention of coronary heart disease. (Current cardiology reports.) Curr Sci 1999;1:112-18.
20. Judah Vague I, Pyke SDM, Alessi M, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63.
21. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999;147:213-25.
22. Fassbender K, Bertsch T, Mielke O, et al. Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke 1999;30:1647-50.
23. Biasucci L, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94:874-7.
24. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
25. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia (ACADEMIC) study. Circulation 1999;99:1540-7.
26. Patel P, Mendall MA, Carrington D, et al. Association of helicobacter pylori and chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311:711-14.
27. Gupta S, Leatham EW, Carrington D, et al. Elevated chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
28. Kol A, Sukhova GK, Lichtman AH, et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998;98:300-7.
29. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-75.
30. Berman JW, Caldron TM. The role of endothelial cell adhesion molecules in the development of atherosclerosis. Cardiovasc Pathol 1992;1:17-28.
31. Stemme S, Rymo L, Hannson GK. Polyclonal origin of T-lymphocytes in human atherosclerotic plaques. Lab Invest 1991;65:654-60.
32. Hansson GK, Holm J, Jonasson L. Detection of T-lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-75.
33. Oksenberg JR, Starvi GT, Jeong MC, et al. Analysis of the T-cell receptor repertoire in human atherosclerosis. Cardiovasc Res 1997;36:256-67.
34. Doukas J, Pober JS. Lymphocyte-mediated activation of cultured endothelial cells. J Immunol 1990;145:1088-98.
35. Davies MJ, Woolf N, Rowles P, et al. Lipid and cellular constituents of unstable human aortic plaques. Basic Res Cardiol 1994;89:33-9.
36. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992;326:242-50/310-18.
37. Schanbeck U, Mach F, Sukhova GK, et al. Regulation of matrix metalloproteinases expression in human vascular smooth muscle cells by T-lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997;81:448-54.
38. Math F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-9.
39. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8.
40. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
41. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content in rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998;97:2433-44.
42. Amberger A, Maczek C, Jurgens G, et al. Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones 1997;2:94-103.
43. Li H, Cybulski MI, Gimbrone MA, et al. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993;13:197-204.
44. Liuzzo G, Baisucci LM, Gallimore JR, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999;34:1696-703.
45. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells: molecular Trojan horses and cellular saboteurs. J Biol Chem 1997;272:22975-8.
46. Shindo J, Ishibashi T, Kijima M, et al. Increased lipoprotein (a) deposition and macrophage number of atherectomy in acute coronary syndromes. Circulation 1998;98(suppl):1-46.
47. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein (a) and inflammation in coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998;32:2035-42.
48. Hamsten A, deFaire U, Walldins G, et al. Plasminogen activator inhibitor in plasma as risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
49. Mizuno O, Hojo Y, Ikeda U, et al. Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol 2000;85:154-60.
50. Maseri A. Inflammation, atherosclerosis and ischemic events - exploring the hidden side of the moon. N Engl J Med 1997;336:1014-15.
51. Miller DL, Yaron R, Yellin MJ. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 1988;63:373-9.
52. Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7.
53. Aikawa M, Voglic SJ, Sugiyama S, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999;100:1215-22.
54. Leathman EW, Bath PM, Tooze JA, et al. Increased monocyte tissue factor expression in coronary artery disease. Br Heart J 1995;73:10-13.
55. Lo SK, Cheung A, Zheng Q, et al. Induction of tissue factor on monocytes by adhesion to endothelial cells. J Immunol 1995;154:4768-77.
56. Annex BH, Denning SM, Keith MC, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91:619-22.
57. Haverkate F, Thompson S, Duckert F. Haemostasis factors in angina pectoris: relation to gender, age, and acute phase reaction. Thromb Haemost 1995;73:561-7.
58. Tracy R. Atherosclerosis, thrombosis and inflammation: a question of linkage. Fibrinolysis Proteolysis 1997;II(suppl 1):137-42.
59. Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
60. Folsom A, Wu K, Rosamond W, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Circulation 1997;96:1102-8.
61. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in non-parallel streamlines: platelets grow at the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989;84:1134-44.
62. Lassila R, Badimon JJ, Valibhajosula S, et al. Dynamic monitoring of platelets deposition on severely damaged vessel wall in flowing blood. Effects of different stenosis on thrombus growth. Arteriosclerosis 1990;10:306-15.
63. Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells. A key role in atherosclerosis? Atherosclerosis 1998;137:S89-95.
64. Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci USA 1983;80:6386-9.
65. Jousilahti P, Vartiaainen E, Tuomilehto J, et al. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996;348:567-72.
66. Mattila KJ, Nieminen MS, Valtonen VV, et al. Association between dental health and acute myocardial infarction. BMJ 1989;298:779-81.
67. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection by Helicobacter pylori with strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-15.
68. Peek RM, Miller GG, Tham KT, et al. Heightened inflammatory response and cytokine-expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest 1995;73:760-70.
69. Pasceri V, Cammarota G, Patti G, et al. Association of virulent Helicobacter pylori strains with ischemic disease. Circulation 1998;97:1675-9.
70. Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in the atherosclerosis of the carotid artery. Circulation 1995;92:3397-400.
71. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555-61.
72. Melnick JL, Hu C, Burek J, et al. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994;42:170-4.
73. Wu TC, Hruban RH, Ambinder RF, et al. Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transpranted hearts. Am J Pathol 1992;140:739-47.
74. Mayr M, Kiechl S, Willeit J, et al. Infections, immunity and atherosclerosis. Associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000;102:833-9.
75. Gurfinkel E, Bozovich G, Daroca A, et al, for the ROXIS Study Group. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
76. Koenig W, Sund M, Frohlich M, et al. C-reactive protein a sensitive marker of inflammation predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999;99:237-42.
77. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
78. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1966;335:1001-9.
79. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol level. Circulation 1998;98:839-44.
80. Davies MJ. Reactive oxygen species, metalloproteinases and plaque stability. Circulation 1998;97:2382-3.
81. Egashira K, Inou T, Yamada A, et al. Impaired coronary blood flow response to acetylcholine in patients with risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91:29-37.
82. Tousoulis D, Gorog D, Crake T, et al. Vasomotor responses of coronary stenoses to acetylcholine and their relation to serum lipid levels in stable angina pectoris. Am J Cardiol 1999;83:1606-10.
83. Mougenot N, Lesnik P, Ramirez-Gil JF, et al. Effect of the oxidation state of LDL on the modulation of arterial response in vivo. Atherosclerosis 1997;133:183-92.
84. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
85. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
86. Stefanadis C, Diamantopoulos L, Vlachopoulos C, et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: a new method of detection by application of a special thermography catheter. Circulation 1999;99:1965-71.